Dara Azar
Stock Analyst at Stifel Nicolaus
(1.86)
# 3,299
Out of 4,444 analysts
11
Total ratings
28.6%
Success rate
1.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dara Azar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Initiated Coverage: Buy | $60 | $47.77 | +25.60% | 1 | Jun 9, 2026 | |
| INBX Inhibrx Biosciences | Maintained: Buy | $325 | $95.14 | +241.60% | 5 | Jun 2, 2026 | |
| SMMT Summit Therapeutics | Maintained: Buy | $45 | $14.25 | +215.79% | 5 | Jun 1, 2026 |
Enliven Therapeutics
Jun 9, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $47.77
Upside: +25.60%
Inhibrx Biosciences
Jun 2, 2026
Maintained: Buy
Price Target: $325
Current: $95.14
Upside: +241.60%
Summit Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $45
Current: $14.25
Upside: +215.79%